Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation

H. Schmidt; H. Einsele; K. Jaschonek; R. Dopfer; G. Ehninger; Arnold Glazier; Gary C. Yee; H. Joachim Deeg

doi:10.1056/NEJM198812153192414

Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation

H. Schmidt, H. Einsele, K. Jaschonek, R. Dopfer, G. Ehninger, Arnold Glazier, Gary C. Yee, H. Joachim Deeg

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Abstract

To the Editor: The findings of Yee et al. (July 14 issue)¹ accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.

Original language	English (US)
Pages (from-to)	1607-1608
Number of pages	2
Journal	New England Journal of Medicine
Volume	319
Issue number	24
DOIs	https://doi.org/10.1056/NEJM198812153192414
State	Published - Dec 15 1988
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM198812153192414

Cite this

@article{f34211e25a024a2ea4ae597cbbd6a473,

title = "Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation",

abstract = "To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.",

author = "H. Schmidt and H. Einsele and K. Jaschonek and R. Dopfer and G. Ehninger and Arnold Glazier and Yee, {Gary C.} and Deeg, {H. Joachim}",

year = "1988",

month = dec,

day = "15",

doi = "10.1056/NEJM198812153192414",

language = "English (US)",

volume = "319",

pages = "1607--1608",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "24",

}

TY - JOUR

T1 - Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation

AU - Schmidt, H.

AU - Einsele, H.

AU - Jaschonek, K.

AU - Dopfer, R.

AU - Ehninger, G.

AU - Glazier, Arnold

AU - Yee, Gary C.

AU - Deeg, H. Joachim

PY - 1988/12/15

Y1 - 1988/12/15

N2 - To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.

AB - To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.

UR - http://www.scopus.com/inward/record.url?scp=0024202566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024202566&partnerID=8YFLogxK

U2 - 10.1056/NEJM198812153192414

DO - 10.1056/NEJM198812153192414

M3 - Letter

C2 - 3059188

AN - SCOPUS:0024202566

SN - 0028-4793

VL - 319

SP - 1607

EP - 1608

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 24

ER -

Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this